<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="136765">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01320891</url>
  </required_header>
  <id_info>
    <org_study_id>HC-I-H-0909</org_study_id>
    <nct_id>NCT01320891</nct_id>
  </id_info>
  <brief_title>Effects of Different Strategy of Fluids Administration on Acid/Base Disorders and Inflammatory Mediators</brief_title>
  <official_title>Effects of Different Strategy of Fluids Administration on Acid/Base Disorders and Inflammatory Mediators</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Università degli Studi di Ferrara</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>B. Braun Melsungen AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Università degli Studi di Ferrara</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of the study is to ascertain whether a different strategy of fluids administration can
      be responsible of differences in terms of acid/base disorders (Stewart approach),
      pro-inflammatory and inflammatory mediators. Hence two groups of patients will be treated
      either with not-balanced solutions (Normal Saline) or balanced solutions
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2010</start_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>acid/base disorder</measure>
    <time_frame>T0: anaesthesia induction (control value) T1: end of surgery T2: 1h after the end of surgery T3: 24h after the beginning of surgery</time_frame>
    <description>the investigators assess difference in acid base disorders between the two groups measuring emogas analyses data and blood electrolites levels at the same time (two days)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pro/antiinflammatory cytokine</measure>
    <time_frame>T0: anaesthesia induction (control value) T1:end of surgery T2: 1h after the end of surgery T3: 24h after the beginning of surgery</time_frame>
    <description>-MMP-9 total and active, TIMP-1, IL-6, IL-8, IL-10, mieloperossidasis, ROS, MCP-3 will be measured during the observation period. (two days)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Carcinoma of the Large Intestine</condition>
  <arm_group>
    <arm_group_label>balanced</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>arm in which the subjects received only balanced solutions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>not balanced</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>arm in which the subjects received only not balanced solutions that means only normal saline and colloid dissolved in normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>balanced solutions</intervention_name>
    <description>during the general anaesthesia until 8 o'clock of the day after the operation the subject will receive only balanced fluids that means balanced crystalloid and colloids dissolved in balanced solution. 12 ml /Kg/h during operation time. ratio 3:1 between crystalloid and colloid.</description>
    <arm_group_label>balanced</arm_group_label>
    <other_name>sterofundin, tetraspan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>not balanced</intervention_name>
    <description>during the operation time until the 8 o'clock of the day after the operation, the subjects will receive only normal saline and colloid dissolved in normal saline.</description>
    <arm_group_label>not balanced</arm_group_label>
    <other_name>Normal saline, Amidolite</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with diagnosis of large bowel cancer

          -  Age &gt; 18 years old

        Exclusion Criteria:

        Emergency surgery for bowel punch or intestinal occlusion

          -  Massive bleeding

          -  Therapy with corticosteroid or nonsteroid antiinflammatory substances

          -  Renal insufficiency (serum creatinine &gt; 200 micromol /l)

          -  Cardiac insufficiency (NYHA III-IV)

          -  Altered liver function (ALT &gt; 40 U/l AST &gt;40 U/l)

          -  Preoperative anaemia ( Hb &lt; 10 g/dl )

          -  Allergy to hydrossietilic starches

          -  Patient rejection to share the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlo A Volta, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Ferrara Univesity</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carlo A Volta, Professor</last_name>
    <phone>0532237005</phone>
    <phone_ext>0039</phone_ext>
    <email>vlc@unife.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lucia Farabegoli, MD</last_name>
    <phone>0532237007</phone>
    <phone_ext>0039</phone_ext>
    <email>farabegolilucia@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>S.Anna Universitary Hospital</name>
      <address>
        <city>Ferrara</city>
        <zip>44100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lucia Farabegoli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <lastchanged_date>March 22, 2011</lastchanged_date>
  <firstreceived_date>March 8, 2011</firstreceived_date>
  <responsible_party>
    <name_title>Prof. Carlo Alberto Volta</name_title>
    <organization>Ferrara University</organization>
  </responsible_party>
  <keyword>general anaesthesia for major abdominal surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
